Actavis (ACT) Tops Q1 EPS by 38c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Guggenheim Raises PT After Actavis (ACT) Has 1Q15 EPS Beat
May 11, 2015 10:57 AM EDTGuggenheim reiterates their Buy rating on Actavis (NYSE: ACT), and raised the price target to $355.00 (from $345.00), following a 1Q15 beat. ACT reported an adjusted 1Q15 diluted EPS of $4.30. This came $0.34 higher than consensus, and $0.41 better than Guggenheim estimates.
Guggenheim analyst, Louise Chen,... More
